Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification
|
|
- Josephine Jefferson
- 5 years ago
- Views:
Transcription
1 Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification David M. Maahs, MD; Lorraine G. Ogden, PhD; Gregory L. Kinney, MPH; Paul Wadwa, MD; Janet K. Snell-Bergeon, MPH; Dana Dabelea, MD, PhD; John E. Hokanson, MPH, PhD; James Ehrlich, MD; Robert H. Eckel, MD; Marian Rewers, MD, PhD Background Circulating adiponectin levels are lower in men than in women and lower in advanced coronary artery disease, obesity, and type 2 but not type 1 diabetes. However, it is not known whether low adiponectin levels predict development of atherosclerosis independently of other cardiovascular risk factors. Methods and Results Progression of coronary artery calcification (CAC) over an average of 2.6 years (range, 1.6 to 3.3) was assessed in a cohort of patients with type 1 diabetes and nondiabetic subjects 19 to 59 years of age. In this nested case-control substudy, plasma adiponectin levels were measured in 101 cases with significant CAC progression and in 205 controls. Controls were oversampled on the basis of age, gender, diabetes status, and presence of baseline CAC. In conditional logistic regression adjusted for baseline CAC volume and other significant predictors of CAC progression, adiponectin levels were inversely related to progression of CAC in diabetic (OR, 0.47; 95% CI, 0.24 to 0.94) and nondiabetic (OR, 0.15; 95% CI, 0.05 to 0.40 for a doubling in adiponectin levels) subjects. Adjustment for additional cardiovascular risk factors did not change this association. In conditional logistic regression models by quartiles of plasma adiponectin levels, the probability value for trend was statistically significant for all participants (P) and nondiabetic participants (P) and was borderline for type 1 diabetics (P 0.08). Conclusions Low plasma adiponectin levels are associated with progression of CAC in type 1 diabetic and nondiabetic subjects independently of other cardiovascular risk factors. (Circulation. 2005;111: ) Key Words: adiponectin coronary disease diabetes mellitus epidemiology risk factors Adiponectin is a 30-kDa, collagen-like protein synthesized by adipocytes that circulates in human plasma as 0.01% of total plasma protein. 1 Adiponectin is lower in men than women and in patients with hypertension or type 2 diabetes (T2DM); it correlates negatively with age, body mass index (BMI), insulin resistance, and levels of plasma insulin, triglycerides, glucose, and C-reactive protein (CRP). 2 9 Conversely, adiponectin is positively correlated with HDL and has been demonstrated to increase in individuals who lose weight. 2,10 Adiponectin accumulates in damaged vascular walls 11 and beneficially modulates the endothelial inflammatory response to vascular injury. 12,13 Given the relationship between adiponectin and obesity and other cardiovascular risk factors, it has been proposed as a link in the adipose-vascular axis 14 and may play a role in the development of atherosclerosis. Indeed, adiponectin has been shown to be lower in patients with advanced coronary artery disease (CAD) than in age-, gender-, and BMI-matched controls. 12 Prospective data demonstrating that adiponectin levels are significantly and independently related to development of atherosclerosis or CAD 12,15 have been reported in patients with end-stage renal disease (ESRD) 16 and in a nested case-control study within the Health Professionals Follow-up Study. 17 In contrast to a significant body of evidence linking low adiponectin to insulin resistance and T2DM, little is known about adiponectin levels in type 1 diabetes (T1DM), which is usually not characterized by insulin resistance. In this prospective case-control study nested within a larger cohort study of young adults with and without T1DM, 18 change in coronary artery calcium (CAC) volume was used as a marker of atherosclerosis progression over a 2.6-year follow-up period. The purpose of this study was to determine significant and independent predictors of progression of CAC and to evaluate the role of adiponectin levels as a potential novel cardiovascular risk factor. Methods Study Subjects The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study is a prospective cohort study designed to assess the develop- Received August 17, 2004; revision received November 23, 2004; accepted November 29, From the Barbara Davis Center for Childhood Diabetes (D.M.M., P.W., M.R.), Department of Preventive Medicine and Biometrics (L.G.O., G.L.K., J.K.S.-B., D.D., J.E.H., M.R.), and Department of Medicine (R.H.E.), University of Colorado Health Sciences Center, and Colorado Heart Imaging (J.E.), Denver, Colo. Correspondence to David M. Maahs, MD, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 E 9th Ave, Denver, CO David.Maahs@uchsc.edu 2005 American Heart Association, Inc. Circulation is available at DOI: /01.CIR A5 747
2 748 Circulation February 15, 2005 ment and progression of subclinical CAD in subjects with T1DM and in nondiabetic (non-dm) controls to identify targets for primary prevention of CAD in this population. The study design has been described in detail elsewhere. 18 Briefly, the study assessed the extent of CAC in a cohort of 654 T1DM and 765 non-dm subjects (excluding 1 participant diagnosed with T2DM at baseline) 19 to 59 years of age at the baseline in 2000 to All subjects were asymptomatic for CAD and had no history of CABG, coronary angioplasty, or unstable angina. All participants with diabetes had been diagnosed when 30 years of age or had a diagnosis of T1DM confirmed by an endocrinologist and had been treated with insulin within 1 year of diagnosis. All non-dm participants reported never having been diagnosed with diabetes of any type, including gestational diabetes, and were generally spouses, friends, and neighbors of the cases. The data presented in this report were collected as part of the follow-up examination of the first 674 members of the CACTI cohort after an average of 2.6 years (range, 1.6 to 3.3 years), which included a nested case-control substudy of 101 participants whose CAC progressed significantly and 205 nonprogressing controls (see below for definition of significant progression and methods for selecting cases and controls). Imaging All patients underwent 2 electron-beam CT (EBCT) scans within 5 minutes without contrast at baseline and 2 scans at follow-up as previously described. 18 Images of the entire epicardial system were obtained with an Imatron C-150 Ultrafast CT scanner with a 100-ms exposure. The standard acquisition protocol previously described was used. 19 Scanning started from near the lower margin of the bifurcation of the main pulmonary artery. Images were electrocardiographically triggered at 80% of the R-R interval, and 30 to 40 contiguous 3-mm slices were acquired. The volume scores were calculated with the volumetric method, which is based on isotropic interpolation as previously described. 20 Definition of CAC Progression In this study, we chose to define progression as reported by Hokanson et al, 21 who noted that bias in the interscan variability of calcium volume scores (CVSs) exists so that the variability increases as levels of coronary calcium increase. If not accounted for, this may lead to overestimation of changes in CVS over time at higher levels of coronary calcium. Alternatively, using percent change in CVS as a potential measure of changes in coronary calcium may underestimate changes at higher levels of coronary calcium. Using paired mean CVS measurements in 1074 subjects who had 2 EBCT scans 5 minutes apart, Hokanson et al 21 found that square root transformation of CVS provides a stable estimate of interscan variability across the ranges of coronary calcium observed in the present study, thus allowing investigations of changes in coronary calcium that are not biased by level of coronary calcium. Furthermore, Hokanson et al suggested using a difference between baseline and follow-up square root transformed CVS of 2.5 to signify a significant change in CVS because a change of this magnitude is 1% likely to be due to interscan variability. Selection of Cases The baseline and follow-up CVSs were square root transformed, and the difference was calculated for each subject. Individuals were categorized as progressors if the change in square root CVS was 2.5. All subjects who qualified as progressors (n 101) at the time of the nested case-control study were included as cases. Regression of CAC would similarly be defined as a reduction in the square root CVS of 2.5; however, none of the patients in this study experienced regression according to this definition. Selection of Controls The remaining 573 subjects were classified as nonprogressors (ie, a change in square root CVS 2.5) and were eligible to be selected as controls. Individual matching of controls to each of the cases was not possible with the number of controls available, yet we wanted to choose controls who would provide us with the most valuable information and thus the most efficient analysis. We therefore oversampled controls on the basis of age, gender, diabetes status, and presence of baseline CAC. Because the majority of cases (70 of 101) but only a minority of controls (79 of 573) had measurable CAC at baseline, we selected all such controls for the nested case-control study. We then selected 126 of the remaining 494 controls to be frequency matched to cases within strata defined by diabetes status, gender, and age group ( 30, 30 to 39, 40 to 49, 50 years). In strata with a sufficient number of controls, we randomly selected twice the number of cases in the stratum. In strata with 2 controls per case, we selected all possible controls in that stratum for inclusion in the present study. Covariate Measurements Laboratory Analyses After subjects fasted overnight, blood was collected and centrifuged, and separated plasma was stored at 4 C until assayed. Adiponectin was measured in the GCRC core laboratory at the University of Colorado Health Sciences Center (Denver) in duplicate with a commercial radioimmunoassay procedure (Linco Research, Inc). Stored samples ( 70 C) from the subjects baseline study visit were diluted 1:500 before testing. Intra-assay precision was 7.5% (3.9% per package insert); interassay precision was 8.5%. Results are reported in micrograms per milliliter, with a sensitivity cutoff of 1.0 ng/ml. Total plasma cholesterol and triglyceride levels were measured with standard enzymatic methods; HDL cholesterol was separated by use of dextran sulfate; and LDL cholesterol was calculated from the Friedewald formula. High-performance liquid chromatography (Bio- Rad variant) was used to measure HbA 1c. Plasma glucose was measured with standard hexokinase method. Homocysteine was determined by the Abbot IMX automated procedure. CRP, plasminogen activator inhibitor type 1 (PAI-1), and fibrinogen were measured in the laboratory of Dr Russell Tracy at the University of Vermont. CRP was measured with the BNII nephelometer (Dade Behring) using a particle-enhanced immunonephelometric assay. PAI-1 was done as a 2-site ELISA. Fibrinogen was measured in an automated clot-rate assay with the Sta-r instrument. Urine albumin excretion was determined by radioimmunoassay, and the results of 2 timed overnight urine collections were averaged. Anthropometric Variables We measured height and weight and calculated BMI. Minimum waist and maximum hip measurements were obtained in duplicate, and the results were averaged. Intra-abdominal fat and subcutaneous fat were assessed with an abdominal CT scan at the L2-L3 levels. The L2-L3 disc space was located by counting the lumbar vertebra, with L1 being the first non rib-bearing vertebra. A single 6-mmthick image was obtained through the L2-L3 disc space during suspended respiration. This process was repeated at the L4-L5 disc space. The total intra-abdominal fat volume and subcutaneous fat volume in cubic centimeters were measured with AccuAnalyzer software from AccuImage. Resting systolic (SBP) and fifth-phase diastolic (DBP) blood pressures were measured 3 times while the patient was seated, and the second and third measurements were averaged. 22 Hypertension was defined as current antihypertensive therapy or untreated hypertension (blood pressure 140/90 mm Hg) at the time of the study visit. Insulin resistance was approximated as the inverse of the estimated glucose disposal rate (EGDR), 23 calculated according to this formula: EGDR WHR 3.29 hypertension HbA 1c, where WHR is waist-to-hip ratio. The equation was derived from hyperinsulinemic euglycemic clamps performed in 24 T1DM partic-
3 Maahs et al Low Adiponectin and Progression of CAC 749 ipants in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. Interview Variables Duration of diabetes was determined by patient self-report. Current and former smoking status was obtained by questionnaire; for smokers, the total number of pack-years was calculated. Statistical Analysis Data are presented as arithmetic means and SD for continuous variables (geometric means and ranges for log-transformed variables) and percentages for categorical variables. Because the observed means for controls were dependent on the sampling scheme, least-squares means adjusted to the distribution of age, gender, diabetes status, and presence of baseline CAC for CAC progressors are reported for controls, and differences between cases and controls were evaluated after adjustment for these factors. Conditional logistic regression models for m:n matched data were estimated with SAS PROC PHREG (SAS Institute Inc). To account for the sampling scheme, all models included diabetes status, gender, and presence of baseline coronary calcium as stratification factors and age as a continuous covariate. Continuous variables were examined for a linear relationship with progression of coronary calcium and were transformed when necessary. A square root transformation was used for baseline CVS, and log transformations were used for triglycerides, albumin excretion rate, and adiponectin levels. ORs and 95% CIs for the effect of adiponectin as a continuous variable are reported per doubling in adiponectin levels on the original scale, which is equivalent to a 0.69-U increase on the log scale (or 1.4-SD increase on the log scale). Subgroup analyses were performed for diabetic and non-dm patients, and differences in reported ORs between diabetic and non-dm subjects were tested through the use of interaction terms. To evaluate the relationship between continuous adiponectin levels and CVS progression, we first fit a base model stratified on the matching factors listed previously, including age and logtransformed adiponectin levels as continuous variables. We then fit a series of models that sequentially adjusted for additional a priori sets of cardiovascular risk factors, including baseline CVS, components of the Framingham risk score (SBP, DBP, LDL cholesterol, HDL cholesterol, and smoking status), anthropometric variables (BMI, waist circumference, and intra-abdominal and subcutaneous fat by CT), and novel cardiovascular disease (CVD) risk factors (CRP, homocysteine, serum creatinine, and urinary albumin excretion rate). Next, we sought a parsimonious model that included only those variables that were independently associated with progression of CVS in a stepwise-backward elimination procedure. This model also considered additional risk factors such as triglycerides, apolipoprotein B, PAI-1, fibrinogen, HbA 1c, and EGDR. We further explored the relationship between quartile of baseline adiponectin and progression of CVS. We tested for a linear trend in logtransformed adiponectin levels across quartiles using a single ordinal variable, with the log of the median adiponectin level within each quartile as its value. Because there was a concern that residual confounding by baseline CVS could bias our results, we also ran our principal models on the subset of cases and controls with no measurable CAC at baseline. Human Subjects The study protocol was reviewed and approved by the Colorado Combined Institutional Review Board. Informed consent was obtained from all participants before enrollment. Results Baseline characteristics of study participants with significant CVS progression (n 101: 69 T1DM, 32 non-dm) and controls (n 205: 112 T1DM, 93 non-dm) are given in Table 1. Because our study design allowed for a variable number of controls per case, it was not unexpected that cases were older, were more likely to be diabetic, were more often male, and had higher baseline CVS compared with controls. The median CVS among the cases increased from 16.1 to 85.1 mm 3 over an average of 2.6 years (range, 1.6 to 3.3 years) of follow-up. After adjustment for age, gender, diabetes status, and presence of baseline CAC (Table 1), CVS progressors had greater risk factors associated with CAD compared with controls, including increased BMI, increased subcutaneous fat, higher blood pressure, and higher plasma levels of homocysteine. Plasma adiponectin levels were 22% higher in controls compared with cases (P). Plasma adiponectin levels were higher in T1DM participants compared with non-dm participants ( versus g/ml, P). Table 2 displays the results for the series of conditional logistic regression models adjusting for the a priori set of cardiovascular risk factors, with sequential adjustment for (1) selection factors (gender, diabetes, and presence or absence of baseline CVS, adjusted for age); (2) the above factors and baseline CVS; (3) all the above factors and components of the Framingham risk score (SBP, DBP, LDL, HDL, smoking); (4) all the above factors and measures of overall and central obesity; and (5) all the above factors plus novel CVD risk factors (CRP, homocysteine, serum creatinine and urinary albumin excretion rate). With adjustment for only those factors used to oversample controls for the study (model 1), a doubling of adiponectin levels was associated with a 54% reduction in the odds of progression for all participants (OR, 0.46; 95% CI, 0.30 to 0.72; P), a 41% reduction in the odds of progression for T1DM participants (OR, 0.59; 95% CI, 0.34 to 1.02; P ), and a 73% reduction in the odds of progression for non-dm participants (OR, 0.27; 95% CI, 0.12 to 0.59; P). As shown in Table 2, sequential adjustment for additional risk factors (models 2 through 5) strengthened the association between adiponectin and CAC progression, although the OR was significantly more protective in non-dm participants compared with T1DM participants in these models (P 0.05 for interaction between diabetes and adiponectin). After additional risk factors were considered and nonsignificant predictors of CAC progression were eliminated, the reduced model (model 6) included in addition to age, gender, baseline CVS, and log-transformed adiponectin levels SBP, BMI, and intra-abdominal fat measures. In this model, the OR for all participants was 0.33 (95% CI, 0.19 to 0.57; P), indicating that a doubling of adiponectin levels was associated with 67% lower odds of CAC progression. This association was somewhat weaker but still significant in T1DM patients (OR, 0.47; 95% CI, 0.24 to 0.94; P ) compared with non-dm subjects (OR, 0.15; 95% CI, 0.05 to 0.40; P), although the interaction between adiponectin and diabetes status did not reach statistical significance (P ). Interactions between gender and adiponectin were also assessed, but none were significant (data not shown). Table 3 presents the results of conditional logistic regression models by quartile of plasma adiponectin level overall and stratified by diabetes status for our principal models. The probability value for trend in log adiponectin for the most parsimonious model (model 6) is highly significant for all
4 750 Circulation February 15, 2005 TABLE 1. Baseline Characteristics of Study Participants With Adjusted* Means for Controls Factor CAC Progressors (n 101) Controls (n 205) Controls, Adjusted* Mean P Age, y Male, n (%) 68 (67) 118 (58) Diabetic, n (%) 69 (68) 112 (55) Baseline CVS 0, n (%) 70 (69) 79 (39) Baseline CVS Square root of baseline CVS Duration of diabetes, y Fasting plasma glucose, mg/dl HbA 1c,% BMI, kg/m Average waist, cm Intra-abdominal fat at L Subcutaneous fat L SBP, mm Hg DBP, mm Hg Adiponectin, g/ml 8.6 ( ) 10.2 ( ) 10.5 LDL cholesterol, mg/dl HDL cholesterol, mg/dl Triglycerides, mg/dl (32 400) 96.8 (25 584) Apolipoprotein B, g/l Insulin resistance (1/EGDR) CRP, g/ml PAI-1, ng/ml Fibrinogen, mg/dl Homocysteine, mol/l Current smoker, n (%) 10/101 (10) 25/205 (12) Ever smoker, n (%) 27/101 (27) 50/205 (24) Average AER, g/min 9.5 ( ) 6.1 ( ) Serum creatinine, mg/dl 1.3 ( ) 1.2 ( ) Values are mean SD when appropriate. *Least-squares means adjusted to the distribution of age, gender, diabetes status, and presence of baseline CAC for CAC progressors. Probability value for difference between cases and controls adjusted for age, gender, diabetes status, and presence of baseline CAC. Reported as geometric mean (range); probability value calculated for the ratio of geometric means. participants (P for log trend ) and non-dm participants (P for log trend ) and of borderline significance for T1DM participants (P for log trend 0.08). As shown in the parsimonious model (model 6), the odds of CAC progression were 82% lower for participants in the highest quartile of baseline adiponectin compared with those in the lowest quartile (OR, 0.18; 95% CI, to 0.52; P for log trend ) when all participants were analyzed together. In subgroup analyses, the odds of CAC progression were 60% lower (OR, 0.40; 95% CI, 0.11 to 1.41; P for log trend 0.08) and 96% lower (OR, 0.04; 95% CI, 0.01 to 0.27; P for log trend ) in the highest compared with lowest quartile of adiponectin for T1DM and non-dm participants, respectively. Table 4 repeats our principal models on the subset of cases (n 31) and controls (n 126) with no measurable CAC at baseline. The OR for the most parsimonious model (model 6) was similar to that for all cases and controls as reported in Table 3 (OR, 0.28 [95% CI, 0.12 to 0.63] versus 0.33 [95% CI, 0.19 to 0.57]). This was also found for non-dm participants (11 cases, 53 controls) (OR, 0.17 [95% CI, 0.05 to 0.65] versus 0.15 [95% CI, 0.05 to 0.40]). In T1DM participants (20 cases, 73 controls), adiponectin had a lower OR, although it did not reach statistical significance (OR, 0.32 [95% CI, 0.08 to 1.20; P 0.09] versus 0.47 [95% CI, 0.24 to 0.94]). For this subanalysis of participants with no CVS at baseline, the diabetes adiponectin interaction was not significant (P 0.52).
5 Maahs et al Low Adiponectin and Progression of CAC 751 TABLE 2. Conditional Logistic Regression of Predictors of CAC Progression Overall and Stratified by Diabetic Status: ORs and 95% CIs for a Doubling of Plasma Adiponectin Levels Conditional Logistic Regression Model (Stratified by Gender, Diabetes, and Presence or Absence of Baseline CAC Adjusted for Age) All Participants (101 Cases, 205 Controls) T1DM Patients (69 Cases, 112 Controls) Non-DM (32 Cases, 93 Controls) P for Diabetes Adiponectin Interaction Model 1: selection factors 0.46 ( ), Model 2: selection factors baseline CVS 0.38 ( ), Model 3: selection factors baseline CVS SBP, DBP, LDL, HDL, smoking Model 4: baseline CVS, age, gender, diabetes SBP, DBP, LDL, HDL, smoking BMI, intra-abdominal fat Model 5: baseline CVS, age, gender, diabetes SBP, DBP, LDL, HDL, smoking BMI, intra-abdominal fat CRP, homocysteine, albumin ejection rate, serum creatinine Model 6: selection factors baseline CVS, SBP, BMI, intra-abdominal fat 0.32 ( ), 0.32 ( ), 0.32 ( ), 0.33 ( ), 0.59 ( ), 0.53 ( ), 0.49 ( ), ( ), 0.47 ( ), 0.47 ( ), 0.27 ( ), ( 0.41), 0.12 ( ), 0.13 ( ), 0.10 ( 0.34), 0.15 ( ), Discussion In summary, low plasma adiponectin was one of the strongest and the most consistent predictors of short-term progression of subclinical coronary atherosclerosis in asymptomatic men and women, although the protective effect of adiponectin appeared to be less robust in T1DM participants than in non-dm study participants. TABLE 3. The major finding in this study is that low plasma adiponectin levels are associated with progression of CVS in both non-dm and T1DM subjects and in both genders independently of other traditional CVD risk factors. This is the first report demonstrating that plasma adiponectin levels predict progression of coronary atherosclerosis in both a T1DM and non-dm population, adding significantly to pre- Conditional Logistic Regression Models by Quartile of Plasma Adiponectin Level Overall and Stratified by Diabetic Status Quartile of Adiponectin P for Trend All participants Plasma adiponectin level, median (range), g/ml 5.2 ( ) 8.3 ( ) 11.0 ( ) 17.0 ( ) Cases, n Controls, n Model ( ) 0.30 ( ) 0.22 ( ) Model ( ) 0.21 ( ) 0.17 ( 0.44) Model ( ) 0.25 ( ) 0.18 ( 0.52) T1DM Patients Plasma adiponectin level, median (range), g/ml 6.2 ( ) 10.0 ( ) 13.6 ( ) 20.2 ( ) Cases, n Controls, n Model ( ) 0.29 ( ) 0.42 ( ) Model ( ) 0.27 ( ) 0.38 ( ) 0.05 Model ( ) 0.32 ( ) 0.40 ( ) 0.08 Non-DM patients Plasma adiponectin level, median (range), g/ml 4.0 ( ) 6.7 ( ) 8.7 ( ) 12.0 ( ) Cases, n Controls, n Model ( ) 0.20 ( 0.70) 0.16 ( ) Model ( ) 0.11 ( 0.46) 0.05 ( ) Model ( ) 0.12 ( 0.52) 0.04 ( )
6 752 Circulation February 15, 2005 TABLE 4. Conditional Logistic Regression of Predictors of CAC Progression for Subjects With no Measurable CAC at Baseline Overall and Stratified by Diabetic Status. ORs and 95% CIs for a Doubling of Plasma Adiponectin Levels Conditional Logistic Regression Model (Stratified by Gender and Diabetes, Adjusted for Age) All Participants (31 Cases, 126 Controls) T1DM Patients (20 Cases, 73 Controls) Non-DM Patients (11 Cases, 53 Controls) P for Diabetes Adiponectin Interaction Model 1: selection factors 0.28 ( ), 0.28 ( ), ( ), Model 6: selection factors SBP, 0.28 ( ), ( ), ( ), BMI, intra-abdominal fat vious limited evidence for an inverse relationship between circulating adiponectin levels and CAD. 2,15,16 In addition, a recent nested case-control study from the Health Professionals Follow-up Study reported that in men 40 to 75 years of age, high adiponectin levels were associated with a lower risk of myocardial infarction. 17 The use of CAC as a marker of CAD rather than traditional end points such as coronary artery stenosis, myocardial infarction, or death is one of the limitations of our study. Although longer follow-up of larger populations is necessary to establish that low adiponectin levels predict development of clinical disease, CAC has generally been accepted as a quantifiable, reliable, noninvasive marker of the extent of coronary atherosclerosis. 24 CAC scores (absolute and percentile ranked) and the rate of subclinical progression in calcification as measured by EBCT have been shown to predict both fatal and nonfatal coronary events. 25,26 To maximize precision of outcome measurement, 2 scans were performed at both baseline and follow-up, and statistical analyses were performed to render CVS scores with stable variance. The fact that the observed associations between low adiponectin levels and CVS progression were present in both non-dm and T1DM patients and in men and women and did not change in strength with sequential adjustment for multiple CVD risk factors demonstrates the internal validity of the findings. Overall and among non-dm participants with no baseline CVS, the protective effect of adiponectin was similar to that when all baseline CVS scores are included. Few data exist on the measurement of insulin resistance in T1DM subjects; for this study, we used the method with the best supporting data. 23 Further study is needed on the degree of insulin resistance in subjects with T1DM and how this can best be measured in epidemiological and clinical studies. In T1DM participants, however, the OR was lower (0.32 for T1DM participants with no baseline CVS versus 0.47 for T1DM regardless of baseline CVS). Additionally, for T1DM participants, the OR unexpectedly increased in the quartile with the highest adiponectin levels compared with the second and third quartiles. Renal function has been hypothesized to be a determinant of adiponectin levels; therefore, renal function (as measured by serum creatinine) was analyzed by adiponectin quartile. Although serum creatinine was highest in the highest quartile of adiponectin (geometric least-squares means quartiles 1 through 4: 1.23, 1.23, 1.18, and 1.39; P for log trend ), serum creatinine was not significantly associated with CAC progression in our data and thus could not explain the higher-than-expected odds of CAC progression in the highest quartile of adiponectin. Given the small sample size (16 cases, 29 controls in the fourth quartile), this hypothesis requires future study in the full CACTI cohort. There is a growing body of evidence for the beneficial role of adiponectin in the process of atherosclerosis. 2,12,15 17 Proposed mechanisms by which adiponectin exerts protective effects include suppression of tumor necrosis factor- induced endothelial adhesion molecule expression, macrophage-to foam cell transformation, and tumor necrosis factor- expression in macrophage tissue. 9,12,27 Further clinical and mechanistic studies of adiponectin in relationship to CAD are needed. A reciprocal association of CRP and adiponectin has been reported, 9 but this association was not noted in the present study, nor was CRP a significant predictor of CAC progression in this study after adjustment for age, gender, diabetes, and baseline CAC. This may suggest that CRP is less proximal to the process of coronary atherosclerosis than adiponectin; however, a longer follow-up is needed to assess whether the predictive value of CRP for coronary events is secondary to its correlation with adiponectin levels. Our data confirm higher levels of adiponectin in T1DM patients compared with age- and BMI-matched controls 28,29 or subjects with T2DM. Patients with ESRD are the only other population previously shown to have elevated levels of adiponectin. 16 Potential mechanisms of elevated adiponectin levels in T1DM and ESRD patients include diminished adiponectin clearance rates as a result of impaired renal function. 7 Additional factors may play a role because adiponectin levels are higher in patients with both ESRD and T1DM compared with those with ESRD and T2DM or non-dm ESRD patients. 30 CAD is the main cause of death in T1DM, with 35% mortality caused by CAD in T1DM patients by 55 years of age in contrast to 4% of non-dm women and 8% of men. 31 Therefore, the promising role of adiponectin as a predictor of and potential therapeutic target for prevention of CAD deserves further investigation. In conclusion, low plasma adiponectin levels are associated with progression of subclinical coronary atherosclerosis in people with T1DM and in non-dm subjects independently of other cardiovascular risk factors. These results need to be confirmed in prospective studies of diabetic and non-dm populations, with clinical disease as the primary outcome. Acknowledgments Support for this study was provided by NIH National Heart, Lung and Blood Institute grant R01 HL61753 and DERC Clinical Investigation Core P30 DK Support for Dr Maahs was provided by NIH NIDDK grant T32 DK This study was performed at the Adult General Clinical Research Center at the University of Colorado Health Sciences Center supported by the NIH M01
7 Maahs et al Low Adiponectin and Progression of CAC 753 RR00051, at the Barbara Davis Center for Childhood Diabetes (Denver, Colo), and at the Colorado Heart Imaging Center (Denver). Disclosure Dr Ehrlich is the medical director of and a shareholder in coronary imaging centers that use electron beam tomography scanners. References 1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257: Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20: Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86: Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87: Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51: Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003;88: Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148: Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26: Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107: Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86: Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32: Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100: Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277: Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis: the missing link of adipovascular axis. J Biol Chem. 2002;277: Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23: Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13: Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291: Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003;52: Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15: Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology. 1998;208: Hokanson JE, Mackenzie T, Kinney G, Snell-Bergeon JK, Dabelea D, Ehrlich J, Eckel RH, Rewers M. Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. AJR Am J Roentgenol. 2004;182: Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49: Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995;92: Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, Chomka EV, Liu K. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107: Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228: Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a camp-dependent pathway. Circulation. 2000;102: Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Yamagata K, Miyagawa J, Matsuzawa Y. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care. 2002;25: Perseghin G, Lattuada G, Danna M, Sereni LP, Maffi P, De Cobelli F, Battezzati A, Secchi A, Del Maschio A, Luzi L. Insulin resistance, intramyocellular lipid content and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab. 2003;285:E Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 2004;65: Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile- onset, insulindependent diabetes mellitus. Am J Cardiol. 1987;59:
ATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationObesity, defined as excess fat accumulation, is the most
Association of Hypoadiponectinemia With Coronary Artery Disease in Men Masahiro Kumada, Shinji Kihara, Satoru Sumitsuji, Toshiharu Kawamoto, Satoru Matsumoto, Noriyuki Ouchi, Yukio Arita, Yoshihisa Okamoto,
More informationAtherosclerotic diseases are the leading cause of death in
Adiponectin and Metabolic Syndrome Yuji Matsuzawa, Tohru Funahashi, Shinji Kihara, Iichiro Shimomura Abstract In this review article, the crucial roles of adipocytes in the development of so-called metabolic
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationDiabetic patients experience higher cardiovascular
Effect of Type 1 Diabetes on the Gender Difference in Coronary Artery Calcification: a Role for Insulin Resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study Dana Dabelea, 1 Gregory
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationDiabetes Care 26: , 2003
Pathophysiology/Complications O R I G I N A L A R T I C L E Progression of Coronary Artery Calcification in Type 1 Diabetes The importance of glycemic control JANET K. SNELL-BERGEON, MPH 1 JOHN E. HOKANSON,
More informationDecreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Decreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
More informationFinancial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017
Coronary Artery Calcification Dharmendra A. Patel, MD MPH Director, Echocardiography Laboratory Associate Program Director Cardiovascular Disease Fellowship Program Erlanger Heart and Lung Institute UT
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationRepeatability Limits for Measurement of Coronary Artery Calcified Plaque with Cardiac CT in the Multi-Ethnic Study of Atherosclerosis
Cardiac Imaging Original Research Chung et al. CT of Coronary Artery Plaque Cardiac Imaging Original Research Hyoju Chung 1 Robyn L. McClelland 1 Ronit Katz 1 J. Jeffrey Carr 2 Matthew J. Budoff 3 Chung
More informationRelationship to visceral adiposity, insulin sensitivity, and -cell function
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Adiponectin in Youth Relationship to visceral adiposity, insulin sensitivity, and -cell function FIDA BACHA, MD
More informationCoronary Artery Calcification
Coronary Artery Calcification Julianna M. Czum, MD OBJECTIVES CORONARY ARTERY CALCIFICATION Julianna M. Czum, MD Dartmouth-Hitchcock Medical Center 1. To review the clinical significance of coronary heart
More informationCoronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes
Diabetologia (2005) 48: 379 385 DOI 10.1007/s00125-004-1640-z ARTICLE P. D. Reaven. J. Sacks. Investigators for the VADT Coronary artery and abdominal aortic calcification are associated with cardiovascular
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationKumar S, Sharma S. Department of Cardiac Radiology, AIIMS, New Delhi, India
REVIEW ARTICLE Coronary Artery Calcium Scoring by Cardiac CT as A Screening Tool in 40-45 Years Age Group Predictor of Future Risk for Cardiovascular Events- Systemic Review Kumar S, Sharma S Department
More informationElectron-Beam Tomography Coronary Artery Calcium and Cardiac Events
Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate- Adults George T. Kondos, MD; Julie Anne Hoff, PhD, RN; Alexander
More informationCoronary Artery Calcium to Predict All-Cause Mortality in Elderly Men and Women
Journal of the American College of Cardiology Vol. 52, No. 1, 28 28 by the American College of Cardiology Foundation ISSN 735-197/8/$34. Published by Elsevier Inc. doi:1.116/j.jacc.28.4.4 CLINICAL RESEARCH
More informationDevelopment and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes
ORIGINAL ARTICLE Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes Lindsey M. Duca, David M. Maahs, Irene E. Schauer, Bryan C. Bergman,
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationAssociation of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication
Diabetologia (2010) 53:2518 2525 DOI 10.1007/s00125-010-1886-6 ARTICLE Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication D. M. Maahs & L. G.
More informationSerum Uric Acid Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals without Renal Disease
Diabetes Care Publish Ahead of Print, published online August 26, 2010 Serum Uric Acid Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals without Renal Disease Running Title: Uric
More informationMeasurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium
(2004) 28, 1594 1599 & 2004 Nature Publishing Group All rights reserved 0307-0565/04 $30.00 PAPER www.nature.com/ijo Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationImpact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography
Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography Cardiovascular Division, Faculty of Medicine, University of Tsukuba Akira
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationFat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women
ORIGINAL ARTICLE Fat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women Miwa Ryo 1, Tohru Funahashi 1, Tadashi Nakamura 1, Shinji Kihara 1, Kazuaki Kotani
More informationA diponectin is a collagen-like plasma protein produced
528 CARDIOVASCULAR MEDICINE Implications of plasma concentrations of adiponectin in patients with coronary artery disease Y Nakamura, K Shimada, D Fukuda, Y Shimada, S Ehara, M Hirose, T Kataoka, K Kamimori,
More informationAssociations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance
ORIGINAL ARTICLE Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance Hirokazu YOKOYAMA, Hiroshi HIROSE, Hideki OHGO* and Ikuo SAITO Abstract Objective The aim of this study
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationDecrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris
Circ J 2006; 70: 414 418 Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris Soon Jun Hong, MD; Hong Seog Seo, MD; Seung Woon Rha, MD; Dong Joo Oh, MD; Jung Ah Kwon,
More informationCoronary Calcification Improves Cardiovascular Risk Prediction in the Elderly
Coronary Calcification Improves Cardiovascular Risk Prediction in the Elderly Rozemarijn Vliegenthart, PhD; Matthijs Oudkerk, MD, PhD; Albert Hofman, MD, PhD; Hok-Hay S. Oei, MD, PhD; Wim van Dijck, MSc;
More informationJournal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.053
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationThe progressive impairment of carbohydrate
Pathophysiology/Complications O R I G I N A L A R T I C L E Plasma Adiponectin and Leptin Levels, Body Composition, and Glucose Utilization in Adult Women With Wide Ranges of Age and Obesity ALICE S. RYAN,
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationPlasma Levels of Adiponectin, a Novel Adipocyte-Derived Hormone, in Sleep Apnea
Plasma Levels of Adiponectin, a Novel Adipocyte-Derived Hormone, in Sleep Apnea Robert Wolk, Anna Svatikova, Christy A. Nelson, Apoor S. Gami, Kogilan Govender, Mikolaj Winnicki, and Virend K. Somers Abstract
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationSetting The setting was the Walter Reed Army Medical Center. The economic study was carried out in the USA.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project
More informationPossible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Possible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes MASATO FURUHASHI, MD 1,2 NOBUYUKI URA, MD 1 NORIHITO
More informationAtherosclerosis, the major cause of coronary artery disease
Clinical Investigation and Reports Heritability of Coronary Artery Calcium Quantity Measured by Electron Beam Computed Tomography in Asymptomatic Adults Patricia A. Peyser, PhD; Lawrence F. Bielak, DDS,
More informationAssociation of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without Metabolic Syndrome
JMSCR Volume 2 Issue Pages 11-11 May www.jmscr.igmpublication.org Impact Factor-1.114 ISSN (e)-234-1x Association of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without
More informationElectron Beam CT versus 16-slice Spiral CT: How Accurately Can We Measure. Coronary Artery Calcium Volume?
Electron Beam CT versus 16-slice Spiral CT: How Accurately Can We Measure Coronary Artery Calcium Volume? 1 Objective: The purpose of this study is to investigate how accurately we can measure CAC volume
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases
The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital Sungkyunkwan
More informationEffect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
Metabolism Clinical and Experimental 55 (2006) 996 1001 www.elsevier.com/locate/metabol Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationKhurram Nasir, MD MPH
Non-invasive CAD Screening Khurram Nasir, MD MPH Disclosures I have no relevant commercial relationships to disclose, and my presentation will not include off label or unapproved usage. HOW & WHAT WOULD
More informationCorrelation of serum adiponectin level with some biochemical and metabolic factors in stable hemodialysis patients
Open Access Journal of Journal of Parathyroid Disease 15,3(1), http://www.jparathyroid.com Original Correlation of serum adiponectin level with some biochemical and metabolic factors in stable hemodialysis
More informationHIV infection continues to be a major public health
Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study Hossein Bahrami, MD, PhD, MPH; Matthew Budoff, MD; Sabina A. Haberlen, PhD; Pantea Rezaeian,
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAn association between adipokines and insulin. Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin
Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin Fahim Abbasi, 1 James W. Chu, 1 Cindy Lamendola, 1 Tracey McLaughlin, 1 John Hayden, 2 Gerald M. Reaven, 1 Peter
More informationTable S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
More informationAssociations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women The Hoorn Study MARIEKE
More informationOBESITY IS COMMONLY associated with insulin resistance
0021-972X/01/$03.00/0 Vol. 86, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationDespite the availability of effective preventive therapies,
Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals Robert Park, MD; Robert Detrano, MD, PhD; Min Xiang,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAtherosclerotic cardiovascular complications are the major
lasma Concentrations of a Novel, Adipose-Specific rotein, Adiponectin, in Type 2 atients Kikuko Hotta, Tohru Funahashi, Yukio Arita, Masahiko Takahashi, Morihiro Matsuda, Yoshihisa Okamoto, Hiromi Iwahashi,
More informationAdiponectin is an adipose tissuespecific
Pathophysiology/Complications O R I G I N A L A R T I C L E Synthetic Peroxisome Proliferator Activated Receptor- Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationAdipocytes are a rich source of molecules that. Association Between Adiponectin and Mediators of Inflammation in Obese Women
Association Between Adiponectin and Mediators of Inflammation in Obese Women Stefan Engeli, 1 Mareike Feldpausch, 1 Kerstin Gorzelniak, 1 Frauke Hartwig, 1 Ute Heintze, 1 Jürgen Janke, 1 Matthias Möhlig,
More informationPhysical Activity and Coronary calcification ADJ ASSOCIATE PROFESSOR TAN SWEE YAW NATIONAL HEART CENTRE SINGAPORE
Physical Activity and Coronary calcification ADJ ASSOCIATE PROFESSOR TAN SWEE YAW NATIONAL HEART CENTRE SINGAPORE Calcium Scores (CACS) Calcium Scores (CACS) Calcium Scores are indicative of the presence
More informationRisk Factors for CVD in Type 1 Diabetes
Risk Factors for CVD in Type 1 Diabetes Marian Rewers, MD, PhD Professor & Clinical Director, BDC Duality of Interest Declaration I have no conflict of interest in the field covered by my lecture but I
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationIncreased serum C1q-binding adiponectin complex to total-adiponectin ratio in men with multi-vessel coronary disease
Kishida et al. Diabetology & Metabolic Syndrome 214, 6:64 DIABETOLOGY & METABOLIC SYNDROME RESEARCH Open Access Increased serum C1q-binding adiponectin complex to total-adiponectin ratio in men with multi-vessel
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationIntima-Media Thickness
European Society of Cardiology Stockholm, 30th August 2010 Intima-Media Thickness Integration of arterial assessment into clinical practice Prof Arno Schmidt-Trucksäss, MD Institute of Exercise and Health
More informationCoronary Calcium Predicts Events Better With Absolute Calcium Scores Than Age-Sex-Race/Ethnicity Percentiles
Journal of the American College of Cardiology Vol. 53, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.07.072
More informationEarly Adult Risk Factor Levels and Subsequent Coronary Artery Calcification
Journal of the American College of Cardiology Vol. 49, No. 20, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.03.009
More informationDecreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation
European Journal of Endocrinology (2003) 148 657 662 ISSN 0804-4643 CLINICAL STUDY Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation Miyao Matsubara, Katsuhiko
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationAdiponectin is independently associated with glycosylated haemoglobin
European Journal of Endocrinology (2004) 150 201 205 ISSN 0804-4643 CLINICAL STUDY Adiponectin is independently associated with glycosylated haemoglobin José Manuel Fernández-Real, Patricia Botas-Cervero
More informationDecreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios
European Journal of Endocrinology (2003) 148 343 350 ISSN 0804-4643 CLINICAL STUDY Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios Miyao
More informationCardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification
Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical Center, Torrance, CA
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationCoronary Calcium Independently Predicts Incident Premature Coronary Heart Disease Over Measured Cardiovascular Risk Factors
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln US Army Research U.S. Department of Defense 2005 Coronary Calcium Independently Predicts Incident Premature Coronary Heart
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationFriends, Romans, Cardiac Practitioners, lend me your ears; I come here to bury LDL, not to praise him
Friends, Romans, Cardiac Practitioners, lend me your ears; I come here to bury LDL, not to praise him Adapted from Julius Caesar: Act 3, Scene 2, Page 4 An Alternative Viewpoint A Biomedical Approach to
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationObesity Associated Inflammation in African American Adolescents and Adults
CLINICAL INVESTIGATION Obesity Associated Inflammation in African American Adolescents and Adults Stephanie DeLoach, MD, Scott W. Keith, PhD, Samuel S. Gidding, MD and Bonita Falkner, MD Abstract: Background:
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationAdiponectin plasma concentration, type 2 diabetes mellitus, cardiovascular diseases and features of metabolic syndrome
Monika Żurawska-Kliś 1, Jacek Kasznicki 1, Marcin Kosmalski 1, Janusz Śmigielski 2, Józef Drzewoski 1 ORIGINAL 1 Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University
More informationDementia. Inhibition of vascular calcification
FLEMENGHO Dementia Inhibition of vascular calcification Role of matrix Gla protein Yan-Ping Liu, Fang-Fei Wei, Cees Vermeer, and Jan A. Staessen, Research Unit Hypertension and Cardiovascular Epidemiology,
More informationDisclosures CORONARY CALCIUM SCORING REVISITED. Learning Objectives. Scoring Methods. Consultant for M2S, Inc. Coronary Calcium Scoring: Software
CORONARY CALCIUM SCORING REVISITED Disclosures Consultant for M2S, Inc. Julianna M. Czum, MD Director, Division of Cardiothoracic Imaging Department of Radiology Dartmouth Hitchcock Medical Center Assistant
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More information